Valion Bio (VBIO) EBIT Growth (3y) (2024 - 2026)
Valion Bio (VBIO) EBIT Growth (3y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 6.70% |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 8.36% |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 69.02% |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 24.14% |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 44.54% |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 44.34% |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -28.30% |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 81.27% |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | -18.82% |
| 10 | Valion Bio | 404,923.65 | -1.80 Mn | -45,000.00 | 72.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 72.33% |
| Dec 31, 2025 | 26.67% |
| Sep 30, 2025 | 1.32% |
| Jun 30, 2025 | 13.79% |
| Mar 31, 2025 | 12.41% |
| Dec 31, 2024 | 13.51% |
| Sep 30, 2024 | -5.20% |
| Jun 30, 2024 | -6.27% |
| Mar 31, 2024 | -11.90% |